


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) An indole derivative represented by formula (I) or a salt thereof:



(1)

wherein R₁ represents an aryl lower alkyl group, said aryl group may be substituted with one or more groups selected from the group consisting of a halogen atom, an aryl lower alkyl group, an aryl lower alkenyl group, and an aryl lower alkynyl group; and R₂ represents an aryl group, which may be substituted with a lower alkyl group.

2. (Previously Presented) The indole derivative or a salt thereof according to claim 1, wherein R₁ is a halo-aryl lower alkyl group, said aryl group may be substituted with an aryl lower alkynyl group.
3. (Currently Amended) The indole derivative or a salt thereof according to claim 1, wherein said derivative is selected from the group consisting of

3-(2-chloro-4-iodobenzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole,
3-(2-chloro-4-(phenylethynyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole,
3-(2-chloro-4-(2-phenylethynyl)benzyl)-2-methyl-5-((4-ethylbenzene)sulfonylcarbamoyl)indole,
3-(2-chloro-4-(2-phenylethyl)benzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole,
and
3-(4-bromo-2-chlorobenzyl)-2-methyl-5-((4-methylbenzene)sulfonylcarbamoyl)indole.

4. (Previously Presented) A pharmaceutical composition which comprises, as an active ingredient, the indole derivative or a salt thereof according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

- 5. Cancelled
- 6. Cancelled.
- 7. Cancelled.
- 8. Cancelled
- 9. Cancelled.